Scientist shall present study results of Epidemic Kerato-Conjunctivitis (EKC) drug at Diseases and Drug Discovery conference
The studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC) were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.
Dr. Vivien Boniuk, Associate Professor of Ophthalmology, Albert Einstein College of Medicine, associated with the North Shore Long Island Jewish Health System (NSLIJ), will be also presenting additional results from the animal studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC).
Both of the nanoviricide drug candidates evaluated in this pilot study were found to be clinically highly effective against EKC caused by an adenovirus in the rabbit animal model. It has a long term effect. It reduces conjunctival injection (severe redness of the eye) as well as blepharitis (exudate, swelling, matting of fur). There were no SEI’s (Sub-Epithelial Infiltrates) in animals treated with this nanoviricide (0% incidence).
Reduction of poor vision for longer time in severe cases of EKC in humans is caused by the occurrence of SEI’s. So, absence of SEI’s is an excellent indication of a strong therapeutic effect for EKC-Cide™ in human EKC.
Nanoviricide treatment led to both clinical resolution and immune protection against adenovirus. As expected, no antibody response occurred in uninfected animals.
Filed under Eye Care Program, Eye Treatment, Ocular Surface Disease | Tags: College, Epidemic Kerato-Conjunctivitis (EKC), eye, nanoviricide drug, Ocular Diseases and Drug Discovery, Ophthalmology | Comment Below